De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

argenx Inkomsten in het verleden

Verleden criteriumcontroles 0/6

De winst van argenx is gedaald met een gemiddeld jaarlijks percentage van -8%, terwijl de winst van de Biotechs -industrie jaarlijks groeide met 13.4%. De inkomsten zijn groeide met een gemiddeld percentage van 55.2% per jaar.

Belangrijke informatie

-8.0%

Groei van de winst

-1.8%

Groei van de winst per aandeel

Biotechs Groei van de industrie	-3.6%
Inkomstengroei	55.2%
Rendement op eigen vermogen	-4.8%
Nettomarge	-12.3%
Volgende winstupdate	31 Oct 2024

Recente prestatie-updates uit het verleden

Recent updates

Analyst Estimates: Here's What Brokers Think Of argenx SE (EBR:ARGX) After Its Yearly Report

Mar 24

Analysts Have Made A Financial Statement On argenx SE's (EBR:ARGX) Full-Year Report

Mar 05

argenx SE (EBR:ARGX) Shares Could Be 24% Below Their Intrinsic Value Estimate

Feb 23

Getting In Cheap On argenx SE (EBR:ARGX) Is Unlikely

Dec 18

Broker Revenue Forecasts For argenx SE (EBR:ARGX) Are Surging Higher

Jul 28

An Intrinsic Calculation For argenx SE (EBR:ARGX) Suggests It's 31% Undervalued

Jul 17

Revenues Tell The Story For argenx SE (EBR:ARGX)

Jun 20

argenx (EBR:ARGX) Is Using Debt Safely

May 08

We Think argenx (EBR:ARGX) Can Afford To Drive Business Growth

Apr 20

Does argenx (EBR:ARGX) Have A Healthy Balance Sheet?

Dec 27

Opbrengsten en kosten

Hoe argenx geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

ENXTBR:ARGX Opbrengsten, kosten en inkomsten (USD Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven
30 Jun 24	1,660	-204	892
31 Mar 24	1,451	-328	799
31 Dec 23	1,269	-295	712
30 Sep 23	1,029	-234	638
30 Jun 23	835	-397	555
31 Mar 23	639	-511	520
31 Dec 22	441	-710	472
30 Sep 22	286	-909	434
30 Jun 22	146	-907	407
31 Mar 22	381	-595	352
31 Dec 21	528	-408	308
30 Sep 21	510	-373	270
30 Jun 21	526	-319	233
31 Mar 21	206	-573	204
31 Dec 20	62	-608	172
30 Sep 20	75	-535	144
30 Jun 20	70	-359	110
31 Mar 20	73	-275	86
31 Dec 19	93	-181	72
30 Sep 19	72	-109	56
30 Jun 19	68	-104	49
31 Mar 19	70	-47	37
31 Dec 18	33	-76	31
30 Sep 18	41	-56	27
30 Jun 18	44	-47	22
31 Mar 18	50	-46	18
31 Dec 17	49	-34	15
30 Sep 17	42	-30	11
30 Jun 17	39	-25	10
31 Mar 17	23	-29	10
31 Dec 16	18	-22	7
30 Sep 16	17	-20	7
30 Jun 16	14	-17	6
31 Mar 16	12	-17	6
31 Dec 15	11	-17	5
30 Sep 15	10	-16	5
30 Jun 15	9	-14	5
31 Mar 15	7	-12	4
31 Dec 14	7	-12	4
30 Sep 14	6	-10	4
30 Jun 14	7	-8	3
31 Mar 14	7	-9	3
31 Dec 13	7	-8	3

Kwaliteitswinsten: ARGX is momenteel verliesgevend.

Groeiende winstmarge: ARGX is momenteel verliesgevend.

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: ARGX is verliesgevend en de verliezen zijn de afgelopen 5 jaar toegenomen met een snelheid van 8% per jaar.

Versnelling van de groei: Het is niet mogelijk om de winstgroei van ARGX over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.

Winst versus industrie: ARGX is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Biotechs industrie ( -18.6% ).

Rendement op eigen vermogen

Hoge ROE: ARGX heeft een negatief Return on Equity ( -4.79% ), omdat het momenteel verliesgevend is.

argenx Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

argenx SE to Report Fiscal Year 2024 Results on Feb 27, 2025

First quarter 2024 earnings released: US$1.04 loss per share (vs US$0.52 loss in 1Q 2023)

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

argenx SE to Report Fiscal Year 2023 Results on Feb 29, 2024

Recent updates

Argenx Announces Publication in the Lancet Neurology of Pivotal Adhere Study Data in Chronic Inflammatory Demyelinating Polyneuropathy

Is argenx SE (EBR:ARGX) Trading At A 45% Discount?

Independent Non-Executive Director recently sold €1.9m worth of stock

Results: argenx SE Confounded Analyst Expectations With A Surprise Profit

Forecast to breakeven in 2025

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

argenx SE to Report Fiscal Year 2024 Results on Feb 27, 2025

Zai Lab and argenx Announces Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China

argenx SE's (EBR:ARGX) Shares Climb 26% But Its Business Is Yet to Catch Up

argenx SE Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy

Consensus EPS estimates fall by 12%, revenue upgraded

First quarter 2024 earnings released: US$1.04 loss per share (vs US$0.52 loss in 1Q 2023)

argenx SE Appoints Dr. Brian L. Kotzin as Non-Executive Director to the Board of Directors

argenx SE's (EBR:ARGX) CEO Looks Like They Deserve Their Pay Packet

argenx SE Announces Data from its Phase 3 ADHERE Trial Evaluating VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy

Investors Appear Satisfied With argenx SE's (EBR:ARGX) Prospects

argenx Se Advances Clinical Development of Efgartigimod in Primary Sjogren's Disease

Argenx SE Announces Approval of Vyvgart (Efgartigimod Alfa) in Japan for Adults with Primary Immune Thrombocytopenia

Analyst Estimates: Here's What Brokers Think Of argenx SE (EBR:ARGX) After Its Yearly Report

Consensus EPS estimates upgraded to US$1.43 loss

Consensus estimates of losses per share improve by 13%

Analysts Have Made A Financial Statement On argenx SE's (EBR:ARGX) Full-Year Report

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

argenx SE (EBR:ARGX) Shares Could Be 24% Below Their Intrinsic Value Estimate

argenx SE Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy

argenx SE Announces Approval of VYVDURA (efgartigimod Alfa and Hyaluronidase-qvfc) Injection for Subcutaneous Use in Japan for Generalized Myasthenia Gravis

argenx SE, Annual General Meeting, May 07, 2024

CEO & Executive Director recently sold €1.0m worth of stock

Price target decreased by 11% to €459

argenx SE Reports Topline Results from ADDRESS Study of Efgartigimod SC in Pemphigus

Getting In Cheap On argenx SE (EBR:ARGX) Is Unlikely

Forecast to breakeven in 2025

Forecast to breakeven in 2025

Consensus EPS estimates upgraded to US$4.76 loss, revenue downgraded

argenx SE Reports Topline Results from ADVANCE-SC Study of VYVGART Hytrulo in Primary Immune Thrombocytopenia

Consensus EPS estimates fall by 17%

argenx SE Announces European Commission Approval of Subcutaneous VYVGART (efgartigimod alfa) for Generalized Myasthenia Gravis

Argenx Se Announces 20 Presentations of Clinical Trial and Real-World Data from Studies of Vyvgart® and Vyvgart Hytrulo® (Vyvgart) in Neuromuscular Autoimmune Disease

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus estimates of losses per share improve by 16%

Consensus EPS estimates fall by 19%

Independent Chairman of the Board recently sold €3.8m worth of stock

Argenx Announces VYVGART (Efgartigimod Alfa) Authorized for Sale by Health Canada for Generalized Myasthenia Gravis

CEO & Executive Director exercised options to buy €36m worth of stock.

CEO & Executive Director recently sold €1.9m worth of stock

Independent Non-Executive Director exercised options and sold €3.3m worth of stock

Consensus EPS estimates upgraded to US$4.71 loss

Consensus revenue estimates increase by 10%

Price target increased by 8.0% to €491

Broker Revenue Forecasts For argenx SE (EBR:ARGX) Are Surging Higher

argenx SE to Report Fiscal Year 2023 Results on Feb 29, 2024

New minor risk - Shareholder dilution

Price target increased by 9.4% to €476

New major risk - Share price stability

Consensus EPS estimates upgraded to US$5.73 loss

Zai Lab and argenx Report Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy

Forecast to breakeven in 2025

Zai Lab and argenx Report Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy

An Intrinsic Calculation For argenx SE (EBR:ARGX) Suggests It's 31% Undervalued

Zai Lab Limited and argenx Announce Approval of VYVGART (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China

argenx SE Announces U.S. Food and Drug Administration Approval of VYVGART Hytrulo Injection for Subcutaneous Use in Generalized Myasthenia Gravis

Revenues Tell The Story For argenx SE (EBR:ARGX)

Now 20% undervalued

Consensus EPS estimates upgraded to US$6.53 loss

Now 21% undervalued

Consensus estimates of losses per share improve by 13%

argenx (EBR:ARGX) Is Using Debt Safely

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Forecast to breakeven in 2025